As crises pile up, Bristol CEO relies on board allies

Article Abstract:

Chief Executive Officer Peter R. Dolan of Bristol-Myers Squibb Co. of the United States has weathered an accounting investigation and kept his post. Responsibility for the accounting scandal was found with two former executives who were indicted and a deferred prosecution agreement is in place whereas the pharmaceutical giant's accounting operations are clean over the next two years there will be no criminal charges. Mr. Dolan's management strategy has a steady stream of new drugs in development.

Pharmaceutical preparations, Evaluation, Pharmaceutical industry, Investigations, Company Profile, Bristol-Myers Squibb Co., BMY, Dolan, Peter R.

---

Computer Associates names new CEO

Article Abstract:

Software company Computer Associates International Inc. has hired John Swainson, a former software developer and executive at IBM, as its new chief executive officer. Swainson replaces Sanjay Kumar who has been charged with criminal securities fraud along with several other of the company's top executives.

Electronic computers, Prepackaged software, Legal/Government Regulation, Computer software industry, Computer industry, Software industry, Cases, Microcomputer industry, International Business Machines Corp., IBM, Appointments, resignations and dismissals, CA Inc., CA, Securities fraud, Kumar, Sanjay (American chief executive officer), Swainson, John, Zar, Ira, Cron, Kenneth

---

Similar abstracts:

• Abstracts: Continent's issues include geography and open borders. Airbus A380 churns up turbulence. Airline accident prevention takes backseat to security
• Abstracts: A Chinese telecom powerhouse stumbles on road to the U.S. German firms accused of slave profits Foreign firms slash U.S. deals
• Abstracts: Private property: the wrangle over a right to riches. Fallen heroine
• Abstracts: Ahold to settle shareholder suit for $1.1 billion. Philips's MedQuist will restate some past financial statements
• Abstracts: EU sets antitrust charges on Visa, renewing its scrutiny of industry. AstraZeneca faces EU antitrust claims

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.